Login / Signup

Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A.

Wei YinDimitrios ArkiloPolyna KhudyakovJim HazelSaurabh GuptaMaria S QuintonJie LinDeborah S HartmanMartin M BednarLaura RosenJens R Wendland
Published in: British journal of clinical pharmacology (2021)
The brain-penetrant LSD1 inhibitor TAK-418 was well tolerated, with pharmacokinetic and pharmacodynamic effects that support further investigation.
Keyphrases
  • dna methylation
  • gene expression
  • white matter
  • resting state
  • functional connectivity
  • amino acid
  • subarachnoid hemorrhage